Article Text

other Versions


Phenotypic characterization of patients with intermediate sweat chloride values: towards validation of the European diagnostic algorithm for cystic fibrosis
  1. Christophe Goubeau (christophe.goubeau{at}
  1. University of Leuven, Belgium
    1. Michael Wilschanski (michaelwil{at}
    1. Hadassah University Hospital, Israel
      1. Veronika Skalická (veronika.skalicka{at}
      1. Faculty Hospital Motol, Czech Republic
        1. Patrick Lebecque (lebecque{at}
        1. Université Catholique de Louvain, Belgium
          1. Kevin Southern (k.w.southern{at}
          1. Royal Liverpool Children's Hospital, United Kingdom
            1. Isabelle Sermet (isabelle.sermet{at}
            1. Hôpital Necker-Enfants Malades, France
              1. Anne Munck (anne.munck{at}
              1. Hôpital Robert Debré, France
                1. Nico Derichs ({at}
                1. Medizinische Hochschule Hannover, Germany
                  1. Peter G Middleton (peter_middleton{at}
                  1. Ludwig Engel Centre for Respiratory Research, Westmead Millennium Institute, Australia
                    1. Lena Hjelte (lena.hjalte{at}
                    1. Karolinska University Hospital Huddinge, Sweden
                      1. Rita Padoan (ritaf54{at}
                      1. Ospedale dei Bambini, Italy
                        1. Maire Vasar (maire.vasar{at}
                        1. Children's Clinic of Tartu University Clinics, Estonia
                          1. Christiane A De Boeck (christiane.deboeck{at}
                          1. University of Leuven, Belgium


                            Background: In patients with symptoms suggestive of cystic fibrosis and intermediate sweat chloride values (30-60mmol/L) extensive CFTR gene mutation analysis and nasal potential difference (NPD) measurement are used as additional diagnostic tests and a positive result in either test provides evidence of CFTR dysfunction. To define the phenotype of such patients and confirm the validity of grouping them, we compared patients with intermediate sweat chloride values in whom either additional CF diagnostic test was abnormal with subjects in whom this was not the case and patients with classic CF.

                            Methods: Phenotypic features were compared in 4 groups: 59 patients with CFTR dysfunction, 46 patients with an intermediate sweat chloride concentration but no evidence of CFTR dysfunction (CF unlikely), 103 CF pancreatic sufficient patients (CF-PS), 62 CF pancreatic insufficient patients (CF-PI).

                            Results: The CFTR dysfunction group had more lower respiratory tract infections (p=0.01), more isolation of CF pathogens (p<0.001) and clubbing (p=0.001) compared with the CF unlikely group but less frequent respiratory tract infections with CF pathogens than CF-PS group (p=0.05). CF-PS patients had a milder phenotype than those with PI. Many features, showed stepwise changes through the patient groups.

                            Conclusion: Patients with intermediate sweat chloride values and 2 CFTR mutations or an abnormal nasal PD measurement have a CF like phenotype compatible with CFTR dysfunction and –as a group- differ phenotypically from patients with intermediate sweat chloride values in whom further CF diagnostic tests are normal as well as from CF-PS and CF-PI patients.

                            Statistics from

                            Review history and Supplementary material

                            Request Permissions

                            If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.